| Systemic Lupus Erythematosus Research | Lifetime | 193 | KR 2 | 99.30 |
| Rheumatoid Arthritis Research and Therapies | Lifetime | 165 | KR 2 | 99.26 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 218 | KR 2 | 98.59 |
| Autoimmune and Inflammatory Disorders Research | Lifetime | 155 | KR 2 | 98.84 |
| Diabetes and associated disorders | Lifetime | 327 | KR 1 | 98.50 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 913 | KR 2 | 98.60 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 268 | KR 2 | 98.02 |
| Psoriasis: Treatment and Pathogenesis | Lifetime | 208 | KR 2 | 98.29 |
| Pharmacological Effects of Natural Compounds | Lifetime | 400 | KR 28 | 97.26 |
| Spondyloarthritis Studies and Treatments | Lifetime | 162 | KR 2 | 98.18 |
| Inflammatory mediators and NSAID effects | Lifetime | 429 | KR 2 | 97.48 |
| Systemic Sclerosis and Related Diseases | Lifetime | 330 | KR 2 | 97.43 |
| Protein Tyrosine Phosphatases | Lifetime | 119 | KR 3 | 96.27 |
| Gout, Hyperuricemia, Uric Acid | Lifetime | 139 | KR 5 | 96.76 |
| Vitamin D Research Studies | Lifetime | 355 | KR 1 | 97.45 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 943 | KR 6 | 97.80 |
| Biosimilars and Bioanalytical Methods | Lifetime | 218 | KR 3 | 96.14 |
| Inflammasome and immune disorders | Lifetime | 372 | KR 6 | 96.48 |
| Vasculitis and related conditions | Lifetime | 351 | KR 5 | 96.76 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 352 | KR 9 | 93.87 |
| Toxin Mechanisms and Immunotoxins | Lifetime | 723 | KR 1 | 94.73 |
| IL-33, ST2, and ILC Pathways | Lifetime | 529 | KR 6 | 95.18 |
| Ocular Diseases and Behçet’s Syndrome | Lifetime | 639 | KR 17 | 95.69 |
| Nutrition, Health and Food Behavior | Lifetime | 479 | KR 301 | 93.31 |
| Macrophage Migration Inhibitory Factor | Lifetime | 263 | KR 5 | 92.11 |
| Psychosocial Factors Impacting Youth | Lifetime | 698 | KR 482 | 90.79 |
| Otitis Media and Relapsing Polychondritis | Lifetime | 461 | KR 8 | 88.89 |
| Innovation in Digital Healthcare Systems | Lifetime | 568 | KR 467 | 83.48 |
| Case Reports on Hematomas | Lifetime | 456 | KR 10 | 79.67 |
| Paraoxonase enzyme and polymorphisms | Lifetime | 871 | KR 10 | 65.02 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 92 | KR 1 | 94.51 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 293 | KR 2 | 95.85 |
| Rheumatoid Arthritis Research and Therapies | 2021-2025 | 257 | KR 6 | 96.05 |
| Autoimmune and Inflammatory Disorders Research | 2021-2025 | 235 | KR 2 | 94.47 |
| Psoriasis: Treatment and Pathogenesis | 2021-2025 | 606 | KR 10 | 87.36 |
| Spondyloarthritis Studies and Treatments | 2021-2025 | 612 | KR 18 | 84.22 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 460 | KR 18 | 76.57 |
| Pharmacological Effects of Natural Compounds | 2021-2025 | 948 | KR 45 | 78.62 |
| Vasculitis and related conditions | 2021-2025 | 666 | KR 13 | 81.68 |
| Ocular Diseases and Behçet’s Syndrome | 2021-2025 | 899 | KR 22 | 76.60 |
| IL-33, ST2, and ILC Pathways | 2021-2025 | 898 | KR 26 | 74.74 |
| Heparin-Induced Thrombocytopenia and Thrombosis | 2021-2025 | 633 | KR 19 | 63.08 |
| Case Reports on Hematomas | 2021-2025 | 155 | KR 2 | 63.69 |
| Gout, Hyperuricemia, Uric Acid | 2021-2025 | 1,000 | KR 46 | 61.88 |
| Pain Management and Placebo Effect | 2021-2025 | 966 | KR 18 | 55.81 |
